The European Union’s medicine committee has recommended marketing authorization of Kostaive, a self-replicating mRNA injection for COVID-19, despite the fact it has a 90 percent adverse event rate and non-existent long-term safety data.

During the clinical trials for Kostaive, five deaths were reported among participants in the phase 3b study. Across study phases 1, 2, and 3a combined, 90 percent of injected participants experienced adverse events, with 74.5 percent reporting systemic reactions and 15.2 percent requiring medical attention after the first dose. Notably, many of the study authors are full-time employees of Arcturus Therapeutics, raising concerns about bias in their conclusions.

https://www.lifesitenews.com/opinion/self-amplifying-mrna-covid-shot-nears-approval-in-europe/?